Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptorantagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptorantagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
The conversation discusses topical androgen receptor blockers for hair loss, mentioning Clascoterone, Pyrilutamide, GT20029, and RU58841. Ketoconazole's effectiveness and application methods are also debated.
A 24-year-old male using topical finasteride for hair loss is experiencing thinning despite treatment and has high estrogen levels. He is seeking advice on whether high estrogen could be causing hair loss and how others with high estrogen levels have addressed it.
The conversation discusses the effectiveness of reducing DHT for hair loss treatment and explores alternative approaches like reducing androgen receptor sensitivity. Specific treatments mentioned include finasteride, dutasteride, pyrilutamide (KX-826), GT20029, and RU58841.